Lutetium PSMA
No
No
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Lutetium PSMA
General information
Subsidy Information and Financing Scheme
[MSHL] Lutetium PSMA
Treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen.
Drug Guidance for Subsidy
Not Applicable
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
